DNA vaccines: ready for prime time?

By M. Kutzler, D. Weiner. Nature reviews genetics, 2008

1,079 citations recorded by the source corpus.

Since the discovery, over a decade and a half ago, that genetically engineered DNA can be delivered in vaccine form and elicit an immune response, there has been much progress in understanding the basic biology of this platform. A large amount of data has been generated in preclinical model systems, and more sustained cellular responses and more consistent antibody responses are being observed in the clinic. Four DNA vaccine products have recently been approved, all in the area of veterinary medicine. These results suggest a productive future for this technology as more optimized constructs, better trial designs and improved platforms are being brought into the clinic.

Subfields: Immunology, Molecular Biology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/66cdc1b3b6b13999bcae5d0e9cd21da37d65df1e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Geall
2. A. Verma
3. G. Otten
4. A. Hekele
5. K. Banerjee
6. C. Shaw
7. C. Beard
8. Luis A. Brito

Citations in the corpus

• Nonviral delivery of self-amplifying RNA vaccines (2012, background): “Approaches include administration of nucleic acids in a naked form (simply formulated in buffer); in combination with lipids, polymers, or other compounds; and by physical techniques such as gene gun and electroporation (EP) (2).”